Last $5.93 USD
Change Today +0.09 / 1.54%
Volume 26.8K
OCRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

ocera therapeutics inc (OCRX) Snapshot

Open
$5.75
Previous Close
$5.84
Day High
$6.00
Day Low
$5.74
52 Week High
01/16/14 - $19.94
52 Week Low
08/1/14 - $5.26
Market Cap
117.1M
Average Volume 10 Days
25.1K
EPS TTM
$-1.82
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCERA THERAPEUTICS INC (OCRX)

Related News

No related news articles were found.

ocera therapeutics inc (OCRX) Related Businessweek News

No Related Businessweek News Found

ocera therapeutics inc (OCRX) Details

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company was founded in 2004 and is headquartered in Palo Alto, California.

14 Employees
Last Reported Date: 03/18/14
Founded in 2004

ocera therapeutics inc (OCRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $198.8K
Chief Medical and Development Officer and Dir...
Total Annual Compensation: $398.3K
Compensation as of Fiscal Year 2013.

ocera therapeutics inc (OCRX) Key Developments

Ocera Therapeutics, Inc. Appoints Rajiv Patni as Chief Development Officer

Ocera Therapeutics, Inc. announced that Rajiv Patni, M.D. has been appointed as the company's Chief Development Officer. Dr. Patni will commence his employment with Ocera on September 2, 2014. Prior to joining Ocera, Dr. Patni served as Senior Vice President for Actelion U.S. Prior to his time at Actelion, Dr. Patni served as Vice President at Roche as well as in leadership positions at Novartis and Pfizer.

Ocera Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Ocera Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of USD 33,000. Loss from operations was USD 7,255,000 against USD 2,017,000 a year ago. Net loss from continuing operations was USD 7,243,000 against USD 2,087,000 a year ago. Net loss was USD 7,223,000 against USD 2,087,000 a year ago. Net loss per share from continuing operations- basic and diluted was USD 0.46 against USD 3.24 a year ago. Total net loss per share- basic and diluted was USD 0.46 against USD 3.24 a year ago. For the six months, the company reported total revenue of USD 78,000. Loss from operations was USD 12,450,000 against USD 2,657,000 a year ago. Net loss from continuing operations was USD 12,425,000 against USD 2,818,000 a year ago. Net loss was USD 11,288,000 against USD 2,818,000 a year ago. Net loss per share from continuing operations- basic and diluted was USD 0.80 against USD 4.40 a year ago. Total net loss per share- basic and diluted was USD 0.73 against USD 4.40 a year ago.

Ocera Therapeutics, Inc. to Report Q2, 2014 Results on Aug 11, 2014

Ocera Therapeutics, Inc. announced that they will report Q2, 2014 results at 4:00 PM, US Eastern Standard Time on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCRX:US $5.93 USD +0.09

OCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCRX.
View Industry Companies
 

Industry Analysis

OCRX

Industry Average

Valuation OCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 565.3x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 484.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCERA THERAPEUTICS INC, please visit www.ocerainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.